Market closedNon-fractional
Gossamer Bio/GOSS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Ticker
GOSS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
135
Website
www.gossamerbio.com
Gossamer Bio Metrics
BasicAdvanced
$247M
Market cap
-
P/E ratio
-$0.94
EPS
1.90
Beta
-
Dividend rate
Price and volume
Market cap
$247M
Beta
1.9
Financial strength
Current ratio
7.127
Quick ratio
6.823
Long term debt to equity
736.543
Total debt to equity
782.325
Interest coverage (TTM)
-12.77%
Management effectiveness
Return on assets (TTM)
-43.76%
Return on equity (TTM)
19,905.42%
Valuation
Price to book
9.24
Price to tangible book (TTM)
9.24
Price to free cash flow (TTM)
-1.275
Growth
Earnings per share change (TTM)
-62.18%
3-year earnings per share growth (CAGR)
-35.28%
What the Analysts think about Gossamer Bio
Analyst Ratings
Majority rating from 10 analysts.
Gossamer Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$42M
-12.89%
Profit margin
0.00%
NaN%
Gossamer Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.21
-$0.21
-$0.19
-
Expected
-$0.49
-$0.26
-$0.21
-$0.19
$0.33
Surprise
-7.98%
-17.84%
1.02%
0.47%
-
Gossamer Bio News
AllArticlesVideos
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Benzinga·1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gossamer Bio stock?
Gossamer Bio (GOSS) has a market cap of $247M as of July 27, 2024.
What is the P/E ratio for Gossamer Bio stock?
The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of July 27, 2024.
Does Gossamer Bio stock pay dividends?
No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Gossamer Bio dividend payment date?
Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.
What is the beta indicator for Gossamer Bio?
Gossamer Bio (GOSS) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Gossamer Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.